Harmony Biosciences is trading 1.7% up at $42.75 in pre-market, with the move appearing most consistent with positive broader market sentiment rather than a new company-specific catalyst.
- It closed at $42.02 on September 18, 2026; no fresh company-specific announcement was identified for September 21.
- Recent coverage highlights insider selling under a Rule 10b5-1 plan and strong second-quarter results, including $261.3 million in revenue.
- Major U.S. equity futures are higher alongside technology-led global gains.